CN102292101A - 通过serpine2来调节胶原和平滑肌肌动蛋白表达的组合物和方法 - Google Patents

通过serpine2来调节胶原和平滑肌肌动蛋白表达的组合物和方法 Download PDF

Info

Publication number
CN102292101A
CN102292101A CN2009801553466A CN200980155346A CN102292101A CN 102292101 A CN102292101 A CN 102292101A CN 2009801553466 A CN2009801553466 A CN 2009801553466A CN 200980155346 A CN200980155346 A CN 200980155346A CN 102292101 A CN102292101 A CN 102292101A
Authority
CN
China
Prior art keywords
serpine2
antagonist
expression
collagen
smooth muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801553466A
Other languages
English (en)
Chinese (zh)
Inventor
A.布拉斯
K.沙利文
J.芬纳
E.博希
K.博伊尔
B.旺格
K.皮尔斯
K.巴维
A.达斯
F.法雷尔
P.西瓦库马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Five Prime Therapeutics Inc
Centocor Research and Development Inc
Original Assignee
Five Prime Therapeutics Inc
Centocor Research and Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc, Centocor Research and Development Inc filed Critical Five Prime Therapeutics Inc
Publication of CN102292101A publication Critical patent/CN102292101A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN2009801553466A 2008-11-26 2009-11-25 通过serpine2来调节胶原和平滑肌肌动蛋白表达的组合物和方法 Pending CN102292101A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11818008P 2008-11-26 2008-11-26
US61/118,180 2008-11-26
PCT/US2009/065991 WO2010062995A2 (fr) 2008-11-26 2009-11-25 Compositions et procédés pour réguler l'expression de collagène et d'actine de muscle lisse par la serpine e2

Publications (1)

Publication Number Publication Date
CN102292101A true CN102292101A (zh) 2011-12-21

Family

ID=42133694

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801553466A Pending CN102292101A (zh) 2008-11-26 2009-11-25 通过serpine2来调节胶原和平滑肌肌动蛋白表达的组合物和方法

Country Status (9)

Country Link
US (1) US20100183620A1 (fr)
EP (1) EP2361093A2 (fr)
JP (1) JP2012509941A (fr)
CN (1) CN102292101A (fr)
AU (1) AU2009319772A1 (fr)
CA (1) CA2744555A1 (fr)
IL (1) IL213086A0 (fr)
RU (1) RU2011121042A (fr)
WO (1) WO2010062995A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105263961A (zh) * 2013-05-31 2016-01-20 东亚社会控股株式会社 用于预防、诊断或者治疗癌症或血管发生相关疾病的抗vegf抗体和含有所述抗体的药物组合物
CN109021102A (zh) * 2018-09-01 2018-12-18 无锡傲锐东源生物科技有限公司 抗sma蛋白单克隆抗体及其用途
CN114206938A (zh) * 2019-06-20 2022-03-18 国家医疗保健研究所 抗蛋白酶nexin-1构象单域抗体及其用途
CN114375328A (zh) * 2019-09-06 2022-04-19 学校法人庆应义塾 包含胶质前体细胞的细胞聚集体的制备方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013010045A1 (fr) 2011-07-12 2013-01-17 Biotime Inc. Nouveaux procédés et formulations pour thérapie cellulaire orthopédique
WO2014197421A1 (fr) 2013-06-05 2014-12-11 Biotime, Inc. Compositions et procédés pour la régénération de tissus induite chez des espèces mammaliennes
MX2016005720A (es) 2013-11-04 2016-11-25 Univ Texas Composiciones y metodos para administracion de una enzima a las vias respiratorias de un sujeto.
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
US11175268B2 (en) 2014-06-09 2021-11-16 Biometry Inc. Mini point of care gas chromatographic test strip and method to measure analytes
US11435340B2 (en) 2014-06-09 2022-09-06 Biometry Inc. Low cost test strip and method to measure analyte
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
CA3202332A1 (fr) 2015-12-07 2017-06-15 Agex Therapeutics, Inc. Procedes de re-derivation de diverses cellules de tissu adipeux brun derivees de cellules souches pluripotentes
EP3487407B1 (fr) 2016-07-19 2024-10-02 Biometry Inc. Procédés et systèmes de mesure d'analytes à l'aide de bandelettes réactives pouvant être étalonnées par lots

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5789214A (en) 1988-03-08 1998-08-04 Novartis Finance Corporation Method of inducing gene transcription in a plant
US5614395A (en) 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (fr) 1988-09-02 1997-04-02 Protein Engineering Corporation Production et selection de proteines de liaison diversifiees de recombinaison
US5134076A (en) * 1988-09-27 1992-07-28 The Regents Of The University Of California Monoclonal antibodies specific for protease nexin-1 and puriciation of protease nexin-1 using monoclonal antibodies
EP0462145B1 (fr) 1989-03-07 1994-04-27 Genentech, Inc. Conjugue covalent de lipides et d'oligonucleotides
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1991004753A1 (fr) 1989-10-02 1991-04-18 Cetus Corporation Conjugues d'oligonucleotides non codants et leurs emplois therapeutiques
WO1991006629A1 (fr) 1989-10-24 1991-05-16 Gilead Sciences, Inc. Analogues d'oligonucleotides avec nouvelles liaisons
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5187089A (en) * 1990-06-21 1993-02-16 Incyte Pharmaceuticals, Inc. Protease nexin-i variants which inhibit elastase
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (fr) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methode de production de chainons de paires de liaison specifique
US5639949A (en) 1990-08-20 1997-06-17 Ciba-Geigy Corporation Genes for the synthesis of antipathogenic substances
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69133512T2 (de) 1990-11-23 2006-09-28 Bayer Bioscience N.V. Verfahren zur Transformation monokotyler Pflanzen
CA2405246A1 (fr) 1990-12-03 1992-06-11 Genentech, Inc. Methode d'enrichissement de proteines variantes aux proprietes liantes a lterees
EP0575485A1 (fr) 1991-03-01 1993-12-29 Dyax Corp. Procede de developpement de mini-proteines de liaison
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5593874A (en) 1992-03-19 1997-01-14 Monsanto Company Enhanced expression in plants
ES2227669T3 (es) 1996-01-11 2005-04-01 Immunex Corporation Elementos de secuencia que aumentan la expresion (ease) para sistemas de expresion de eurocariotas.
US5693512A (en) 1996-03-01 1997-12-02 The Ohio State Research Foundation Method for transforming plant tissue by sonication
TWI240723B (en) 2001-06-20 2005-10-01 Wyeth Corp Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
DE60221391T2 (de) 2001-06-20 2008-04-17 Wyeth Substituierte indolsäurederivate als inhibitoren von plasminogen-aktivator-inhibitor-1 (pai-1)
AU2003296324A1 (en) 2002-12-10 2004-06-30 Wyeth Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
UA80453C2 (en) * 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
US7981415B2 (en) 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
US9002656B2 (en) 2011-10-17 2015-04-07 Daxor Corporation Automated total body albumin analyzer

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105263961A (zh) * 2013-05-31 2016-01-20 东亚社会控股株式会社 用于预防、诊断或者治疗癌症或血管发生相关疾病的抗vegf抗体和含有所述抗体的药物组合物
CN105263961B (zh) * 2013-05-31 2019-08-27 东亚社会控股株式会社 用于预防、诊断或者治疗癌症或血管发生相关疾病的抗vegf抗体和含有所述抗体的药物组合物
CN109021102A (zh) * 2018-09-01 2018-12-18 无锡傲锐东源生物科技有限公司 抗sma蛋白单克隆抗体及其用途
CN114206938A (zh) * 2019-06-20 2022-03-18 国家医疗保健研究所 抗蛋白酶nexin-1构象单域抗体及其用途
CN114375328A (zh) * 2019-09-06 2022-04-19 学校法人庆应义塾 包含胶质前体细胞的细胞聚集体的制备方法

Also Published As

Publication number Publication date
CA2744555A1 (fr) 2010-06-03
AU2009319772A1 (en) 2010-06-03
IL213086A0 (en) 2011-07-31
WO2010062995A3 (fr) 2010-07-22
EP2361093A2 (fr) 2011-08-31
RU2011121042A (ru) 2013-01-10
JP2012509941A (ja) 2012-04-26
WO2010062995A2 (fr) 2010-06-03
US20100183620A1 (en) 2010-07-22

Similar Documents

Publication Publication Date Title
CN102292101A (zh) 通过serpine2来调节胶原和平滑肌肌动蛋白表达的组合物和方法
US7575741B2 (en) Methods of treating cutaneous ulcers and grafts using IL-23
EA014106B1 (ru) Агенты, связывающиеся с мишенью в легочной ткани, для лечения респираторных заболеваний
CN108495652A (zh) 用于抑制有需要的受试者的纤维化的方法
MX2011009422A (es) Proteinas mirac.*.
JP6764447B2 (ja) 幹細胞因子阻害剤
US8580255B2 (en) Method for the treatment of rheumatoid arthritis using a TLR2 antagonistic antibody
WO2015120138A2 (fr) Agents modulant la signalisation rgmb-neogénine-bmp et leurs procédés d'utilisation
EP2292758A2 (fr) Utilisations de cytokine de mammifère, réactifs associés
CN118974084A (zh) 减少呼吸系统感染的方法
US9234046B2 (en) Treatment of renal disease
KR101768118B1 (ko) 기도 감염의 치료를 위한 방법 및 약학 조성물
RS65152B1 (sr) Preparati za lečenje granulomatoze sa poliangiitisom
CN105143256A (zh) 血管生成素-2特异性Tie2受体
CN110903397B (zh) 具有降低低密度脂蛋白的pcsk9特异性全人源抗体及其应用
CN108295242A (zh) 用于预防和/或治疗银屑病药物组合物、cd317胞外段蛋白的应用
US20240210419A1 (en) Compositions and methods for detecting and regulating fibronectin-integrin interactions and signaling
HK40118775A (zh) 减少呼吸系统感染的方法
JP2021131228A (ja) 難治性喘息の予防又は治療剤をスクリーニングする方法、及び難治性喘息の予防又は治療剤
NZ702818B2 (en) Stem cell factor inhibitor
NZ612783B2 (en) Stem cell factor inhibitor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20111221